Company Overview
Neogen Corporation is a specialized entity within the healthcare sector that operates specifically in the medical devices industry, focusing on the development, manufacturing, and marketing of products and services designed to ensure food and animal safety in both the United States and international markets. The company organizes its operations through two distinct segments, Food Safety and Animal Safety, providing diagnostic test kits and complementary products to address critical safety needs across these verticals. In terms of scale, the corporation carries a market capitalization of $1.82B and employs a workforce of 2974 individuals, reflecting a significant operational footprint within its niche. The annual revenue generated over the trailing twelve months is $880.32M, a figure that positions the company as a substantial player capable of sustaining complex supply chains and research initiatives, though the valuation suggests the market is weighing recent performance trends against its established size and employee base.
Financial Health
The company reported a trailing twelve-month revenue of $880.32M, yet this top-line figure stands in stark contrast to a net income of $-602,739,008, a gap that reveals a highly fragile cost structure where operating expenses and other costs far exceed the profitability generated from sales. Despite the negative net income, the entity generated an EBITDA of $90.36M, indicating that while accounting for non-cash items and interest taxes creates a loss on the income statement, the core cash earnings from operations before these adjustments remain positive. However, the free cash flow stands at $-924,000, which signals a lack of financial flexibility as the company is currently burning cash rather than generating liquidity to fund internal expansion or debt reduction. Analyzing the margins provides further insight into this financial strain, with a gross margin of 46.0% suggesting efficient production relative to sales, but an operating margin of -2.4% and a profit margin of -68.5% indicating that high administrative or SG&A costs are severely eroding the bottom line. The balance sheet shows a cash position of $145.34M against total debt of $795.07M, resulting in a debt-to-equity ratio of 37.78, which characterizes the company as highly leveraged rather than conservative given the substantial debt load relative to equity. Liquidity is supported by a current ratio of 3.91, which indicates that the company holds sufficient short-term assets to cover its short-term liabilities multiple times over, providing a buffer despite the high leverage. Furthermore, the return on equity is -25.3% and the return on assets is -0.5%, metrics that reveal that management has been ineffective at generating positive returns on the capital invested by shareholders or utilized in the asset base during the reporting period.
Valuation Assessment
The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the negative earnings, while the forward P/E is 25.86, implying that the market is pricing in a significant turnaround in expected earnings trajectory to justify the current multiple. The price-to-book ratio is 0.86, which indicates that the market is valuing the company at less than its book value, suggesting a discount rather than a premium over the net asset value of the firm. Alternative valuation measures provide additional context, with a price-to-sales ratio of 2.07 and an EV/EBITDA of 27.32, suggesting that despite current losses, the market assigns a premium based on sales volume and adjusted earnings power relative to enterprise value. Price volatility is evident in the 52-week range, with a high of $11.43 and a low of $3.87, meaning the stock is currently trading within this established band and reflecting the uncertainty surrounding its earnings path. The beta value of 1.95 indicates that the stock exhibits high price volatility, moving significantly more than the broader market, which introduces substantial risk for investors sensitive to market fluctuations.
Growth & Income
Growth dynamics are currently constrained, as the revenue growth year-over-year is -2.8% and earnings growth is N/A due to the recent loss, indicating that the company is not growing its top line or bottom line at this moment. Because the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, the financial strategy focuses on reinvesting earnings or retaining capital rather than distributing cash to shareholders, which is typical for entities facing negative net income. This absence of a dividend payout highlights a preservation of capital approach, as the firm cannot sustainably pay dividends while managing a net income loss and negative free cash flow. The overall growth and income profile is currently characterized by a contraction in revenue and a complete absence of earnings, with income generation entirely suspended until cost structures can be realigned to support profitability.